News | August 03, 2024
AbbVie completes acquisition of Cerevel Therapeutics
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year / At one-year
Newcastle University’s Dr Srikanth Ramaswamy has been announced as one of six new Fellows selected for the 2023 Lister prize
The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
If approved, ABBV-951 will offer patients the first continuous subcutaneous delivery of carbidopa/levodopa prodrugs
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Subscribe To Our Newsletter & Stay Updated
